A company still losing money, with high risk. Institutions are adding.
Facts from SEC filings, not a recommendation.
From CLYM's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
Last 12 months: -$57.6M.
Price chart by TradingView.
From annual reports filed with the SEC. Not in this company's SEC data, so not scored: net margin 10%+, gross margin 40%+. A checklist is a starting point for research, not a verdict.
No open-market insider buys or sells in the last 90 days.
No trades to chart yet.
SEC filings of any kind. 50 means a normal week.
Institutions added 74.5% to their holdings. 84 bought, 40 sold. 2 quarters of net buying in a row.
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.
70,000 shares at $2.79 avg ($1.29 to $7.89) · $195K
100,000 shares at $13.67 · $1.4M
Source: SEC EDGAR filings. For informational purposes. Not investment advice.
Report a problem with this page